A Phase 3 interventional study of Pitavastatin in Hypercholesterolemia and Dyslipidemias, sponsored by Kowa Research Europe. Completed at 59 sites in 5 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2010-03-16.
Sponsored by Kowa Research Europe (part of Kowa Company, Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing pitavastatin in Hypercholesterolemia — none open to participants now, none under way, none of them phase 3. pitavastatin · Hypercholesterolemia.
Among the 19 studies testing pitavastatin in Hypercholesterolemia, this one is the 5th largest by enrollment, is one of 3 that started in 2006, is one of 9 in phase 3, and was the 7th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →None of the 19 studies testing pitavastatin in Hypercholesterolemia is open now. The open studies under Hypercholesterolemia, anywhere →
pitavastatin: first FDA approval 2009 (LIVALO). What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2006.
This study's enrollment of 545 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 200 across the 19 interventional studies. Of the 19 that completed or were terminated, 11 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 19 have an industry lead sponsor. The 10 most frequent:
This study is registered under Kowa Research Europe, one of the names counted as Kowa Company, Ltd.. Under that name alone:
Kowa Research Europe is the lead sponsor of 10 studies on the registry; none are open to participants now.
11 studies in Hypercholesterolemia by Kowa Company, Ltd.: 1 open now, 1 under way, none of them phase 3. Of 10 finished, 7 (70%) have results posted.
Among the 11 studies in Hypercholesterolemia by Kowa Company, Ltd., this one is the 5th largest by enrollment, is one of 3 that started in 2006, is one of 10 in phase 3, and was the 6th registered.
Kowa Company, Ltd.’s Hypercholesterolemia studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing pitavastatin in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Kowa Company, Ltd.’s 11 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an open-label extension study of NK-104-306 (NCT00257686) for elderly patients with hypercholesterolemia or combined dyslipidemia.
This was an open-label study of 60 weeks duration in elderly patients (≥65 years) with primary hypercholesterolemia or combined dyslipidemia who completed the 12 week treatment in study NK-104-306 and who met the inclusion/exclusion criteria. Patients who qualified started open-label treatment with pitavastatin 2 mg QD. The dose of pitavastatin could be increased to 4 mg QD after at least 8 weeks of treatment at 2 mg QD, in patients who failed to attain their LDL-C target.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Pitavastatin 2 mg once daily
Drug: Pitavastatin
Pitavastatin 4 mg once daily
Drug: Pitavastatin
Change From Baseline in LDL-C
percent change from baseline in low density lipoprotein-cholesterol (LDL-C)
Time frame: Baseline to 60 weeks
Change From Baseline in Total Cholesterol
Percent change from baseline in total cholesterol (TC)
Time frame: Baseline to 60 weeks
| Milestone | Pitavastatin 2 mg QD | Pitavastatin 4 mg QD |
|---|---|---|
| Started | 449 | 90 |
| Completed | 378 | 77 |
| Not completed | 71 | 13 |
percent change from baseline in low density lipoprotein-cholesterol (LDL-C)
| percent change | Pitavastatin 2 mg QD | Pitavastatin 4 mg QD |
|---|---|---|
| Change From Baseline in LDL-C | -43.18 ± 10.065 | -44.26 ± 10.764 |
Percent change from baseline in total cholesterol (TC)
| percent change | Pitavastatin 2 mg QD | Pitavastatin 4 mg QD |
|---|---|---|
| Change From Baseline in Total Cholesterol | -28.27 ± 8.214 | -30.54 ± 8.226 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pitavastatin 2 mg QD | — | 51/449 (11.4%) | — |
| Pitavastatin 4 mg QD | — | 7/90 (7.8%) | — |
| Event | Pitavastatin 2 mg QD | Pitavastatin 4 mg QD |
|---|---|---|
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 6/449 | 0/90 |
| Aortic valve incompetenceCardiac disorders | 0/449 | 1/90 |
| Cporonary artery occlusionCardiac disorders | 0/449 | 1/90 |
| Retinal detachmentEye disorders | 0/449 | 1/90 |
| Urinary tract infectionInfections and infestations | 0/449 | 1/90 |
| Femoral neck fractureInjury, poisoning and procedural complications | 0/449 | 1/90 |
| Cerebrovascular accidentNervous system disorders | 1/449 | 1/90 |
| Peripheral vascular disorderVascular disorders | 0/449 | 1/90 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 4/449 | 0/90 |
| Angina pectorisCardiac disorders | 2/449 | 0/90 |
| Event | Pitavastatin 2 mg QD | Pitavastatin 4 mg QD |
|---|---|---|
| NasopharyngitisInfections and infestations | 71/539 | 2/95 |
| MyalgiaMusculoskeletal and connective tissue disorders | 44/539 | 4/95 |
| HypertensionVascular disorders | 35/539 | 4/95 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 34/539 | 3/95 |
| OsteaoarthritisMusculoskeletal and connective tissue disorders | 24/539 | 5/95 |
| Urinary tract infectionInfections and infestations | 26/539 | 4/95 |
| CystitisInfections and infestations | 26/539 | 1/95 |
| CoughRespiratory, thoracic and mediastinal disorders | 26/539 | 1/95 |
| Age, Categorical(Participants) | Safety Population |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 0 |
| >=65 years | 539 |
| Age Continuous(years) | Safety Population |
|---|---|
| Mean | 70.3 ± 4.73 |
| Sex: Female, Male(Participants) | Safety Population |
|---|---|
| Female | 294 |
| Male | 245 |
The record gives a start of Jun 2006, a primary completion of Dec 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2010, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pitavastatin